Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Trial details
- Registry ID
- NCT02446093
- Phase
- Phase 2
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaNCT02446093 | CADL | Phase 2 | Unknown | 2025-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |